synthetic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-05. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Free acid form of the heptapeptide; depends on terminal groups |
| Molecular mass | About 813.9 g/mol | Average mass used for mass spectrometry confirmation |
| Appearance | White to off-white solid | Supplied as a lyophilised powder; hygroscopic |
| Solubility class | Freely soluble in aqueous media | Water, saline, and phosphate buffers; limited organic solubility |
| Typical storage temperature | -20 degrees Celsius | Long term and dry; short working periods may use 2 to 8 degrees Celsius |
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
== Uses == Along with pharmaceutical applications, it can find utility as food additives, antioxidant, colorant and many other sectors of food industries. Potential pharmaceutical uses of prodigiosin, or its use as a dyestuff, have led to studies of its production from Serratia marcescens, possibly after genetic modification.
Pancreatic secretory trypsin inhibitor (PSTI) also known as serine protease inhibitor Kazal-type 1 (SPINK1) or tumor-associated trypsin inhibitor (TATI) is a protein that in humans is encoded by the SPINK1 gene. In the context of rat biology, it is also sometimes called monitor peptide.
=== Single-nucleotide polymorphisms === A single-nucleotide polymorphism (SNP) is a genetic variation in which a genome sequence is altered by a single nucleotide (A, T, C or G). NET proteins with an altered amino acid sequence (more specifically, a missense mutation) could potentially be associated with various diseases that involve abnormally high or low plasma levels of norepinephrine due to altered NET function. NET SNPs and possible associations with various diseases are an area of focus for many research projects. There is evidence suggesting a relationship between NET SNPs and various disorders such as ADHD psychiatric disorders, postural tachycardia and orthostatic intolerance. The SNPs rs3785143 and rs11568324 have been related to attention-deficit hyperactivity disorder. Thus far, however, the only confirmed direct association between a SNP and a clinical condition is that of the SNP, Ala457Pro, and orthostatic intolerance. Thirteen NET missense mutations have been discovered so far.
Sources: en.wikipedia.org
=== Meningitis === Blood procalcitonin levels can help confirm bacterial meningitis and, if negative, can effectively rule out bacterial meningitis. This was shown in a review of over 2000 patients in which PCT had a sensitivity of 86% and a specificity of 80% for cerebrospinal fluid PCT. Blood PCT measurements proved superior to cerebrospinal fluid PCT with a sensitivity of 95% and a specificity of 97% as a marker for bacterial meningitis. In acute meningitis, serum PCT is useful as a biomarker for sepsis. It can also be of use in determining viral meningitis versus bacterial meningitis. These findings are the result of a 2018 literature review. This followed a 2015 meta analysis that showed that PCT had a sensitivity of 90% and a specificity of 98% in judging viral versus bacterial meningitis. PCT also outperformed other biomarkers such as C-reactive protein.
== References == Crowl, Philip A. (1995). The Pacific War: Campaign in the Marianas. United States Army in World War II. United States Army Center of Military History. ISBN 978-0-16-089915-7. LCCN 60-60000. Archived from the original on 21 July 2022. Retrieved 10 February 2017. Hoyt, Edwin Palmer (1986). Japan's War: The Great Pacific Conflict, 1853 to 1952. New York: McGraw-Hill. ISBN 0-07-030612-5. Morison, Samuel Eliot (1953). New Guinea and the Marianas, March 1944 – August 1944. History of United States Naval Operations in World War II. Vol. VIII. Little, Brown and Company. Polmar, Norman (2008). Aircraft Carriers: A History of Carrier Aviation and Its Influence on World Events, 1946–2006. Vol. II. Washington, D.C.: Potomac Books. pp. 377–400. ISBN 978-1-57488-665-8. Archived from the original on 21 July 2022. Retrieved 1 June 2014. Potter, E. B. (1990). Admiral Arleigh Burke. Naval Institute Press. ISBN 978-1-59114-692-6. Roscoe, Theodore (1949). Pig Boats. New York: Bantam Books. ISBN 978-0-553-13040-4. {{cite book}}: ISBN / Date incompatibility (help) Shaw, Henry I. Jr.; Nalty, Bernard C.; Turnbladh, Edwin T. (1966). "Strategic Victory in the Marianas Liberation of Guam; Capture of Saipan and Tinian". Central Pacific Drive (PDF). History of U.S. Marine Corps Operations in World War II. Vol. III. Historical Branch, G-3 Division, Headquarters, U.S. Marine Corps. Archived (PDF) from the original on 26 January 2021. Retrieved 25 November 2020. Shores, Christopher (1985). Duel for the Sky: Ten Crucial Battles of World War II. London: Grub Street. ISBN 978-0-7137-1601-6.
=== Rats === The copper level of rats that are exposed to crude oil noticeably shrank which indicates ejection of copper with lack of its absorption. Synthesis of catecholamine which enables total functions of body, emotions, and perception may be hindered by reduction of copper concentration. In addition to it, a rise in the activities of superoxide dismutase (SOD), chloramphenicol acetyltransferase (CAT), and glutathione S-transferase (GST) enzymes, in proportion to dose was seen in the rats, which were treated with BLCO for 21 days in a row. This phenomenon means induction of enzymes and especially in the case of GST, its increase may contribute to the availability of glutathione (GSH). Adedara and Farombi say that "Elevated level of intracellular hepatic GSH concentration observed in the BLCO-treated rats indicates an adaptive response to reduce damage and promote better survival under the conditions of oxidative stress induced by BLCO treatment". The elicitation of GSH in testes and sperm is controlled by BLCO. In contrast to rats treated for 21 days, the activities of those enzymes in rats exposed to BLCO for 45 days were decreased. Furthermore, in terms of sperms, noticeable shrink in mobility, number, and life/dead ratio was shown and total abnormality was elevated. However, abnormalities in sperms occurred by bonny light oil were able to be relieved with the help of vitamin E or quercetin. They have functions that restore normal hormonal levels and sperm parameters as well as inhibit oxidation.
Sources: en.wikipedia.org
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.
It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.
Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.